

**"The rare anaplastic sarcoma of the kidney: a case report and literature review"** (NO: 54197) by Kao et al., for publication in **World Journal of Clinical Cases**.

**Response to Reviewer 1:**

**#1. Anaplastic sarcoma of the kidney (ASK) is a rare and newly recognized renal neoplasm. To date, only 27 cases have been reported in the literature. So the authors present an additional case to share the experience on an extremely rare entity.**

**Remedy:**

Thank you very much for your positive comment. We are deeply and sincerely honored by the time and effort you spent in reviewing our manuscript.

**"The rare anaplastic sarcoma of the kidney: a case report and literature review"** (NO: 54197) by Kao et al., for publication in **World Journal of Clinical Cases**.

**Response to Reviewer 2:**

**#1. The authors reported the rare case of anaplastic sarcoma of the kidney. Overall, the case is clearly presented and the manuscript is well written, therefore can be considered for its publication as in this form.**

**It would be nice, however, if the authors could add the information of the chemotherapy summarized in Table. (for e.g., the regimen or the chemo used)**

**Remedy:**

Thank you very much for your positive comment. Regarding the chemotherapy regimen, the currently reported case did not receive chemotherapy before and after the radical nephrectomy. We have added a clear statement in the main text. Also, we could not find the chemotherapy regimen of the previous 27 reported cases in the literature review. Thus, it is a pity that we could not summarize the chemotherapy regimen in Table 1. However, we have added more information about the chemotherapy regimen in the discussion section.

(Please refer to "CASE PRESENTATION," pp.8. and "DISCUSSION," pp.9)

We are deeply and sincerely honored by the time and effort you spent in reviewing our manuscript.

"The rare anaplastic sarcoma of the kidney: a case report and literature review" (NO: 54197) by Kao et al., for publication in **World Journal of Clinical Cases**.

### Response to Reviewer 3:

**#1. This case report presents a rare type of sarcoma of the kidney with poor outcome. The report needs improvement of its English and a couple of other revisions. I will provide below the suggested changes:**

- Abstract, Case summary, first sentence: Change "...healthy woman who presented with..." to "...healthy woman presented with..."
- Core tip, second sentence. Change to "The authors summarized the demographic, clinical, and prognostic features of the 28 ASK cases reported in the literature."
- Core tip, third sentence and Conclusion, last word: Change "prognoses" to "prognosis"
- Case presentation, 1st paragraph, 3rd sentence. change "..., and the bodyweight loss..." to "...and body weight loss..."
- Discussion, 1st paragraph, 3rd sentence: Change "Whereas ASK is..." to "ASK is..."
- Discussion, 2nd paragraph 3rd sentence: Change "...the definite diagnosis..." to "the definitive diagnosis..."
- Discussion, 2nd paragraph, 3rd sentence: change " ...and CT scan; that were predominant..." to "...or CT scan, and the presence of predominant..."
- Discussion, 5th paragraph (bottom in page 9), 2nd sentence: change "In the total 28 patients,..." to "In these 28 patients,..."
- Discussion, 5th paragraph, 3rd sentence: Change the first part of the sentence to "Female sex (67.9% of the 28 patients) and right kidney involvement (68% of the 25 patients with known tumor site) were more frequent..."

### **Remedy:**

We express our extremely hearty appreciation to you for the kind and excellence comments on our manuscript. We also have the manuscript English-edited again by Dr. Tsung, who is a native English speaker and had worked in the United State as a pathologist for about 40 years before working in Taiwan in recent 5 years. Thanks very much.

**#2. Types of chemotherapy used to treat this tumor should be presented in the Discussion**

### **Remedy:**

Regarding the chemotherapy regimen, the currently reported case did not receive chemotherapy before and after the radical nephrectomy. We have added a clear statement in the main text. Also, we could not find the chemotherapy regimen of the previous 27 reported

cases in the literature review. Thus, it is a pity that we could not summarize the chemotherapy regimen in Table 1. However, we have added more information about the chemotherapy regimen in the discussion section.

(Please refer to “CASE PRESENTATION,” pp.8. and “DISCUSSION,” pp.9)

**#3. The proposed management of this variety of renal sarcoma in the Conclusion section should be changed. My suggestion, based on the findings in Table 1 of lethal outcome in a 5-year old patient and in two patients who were initially classified as having stage 1 of the disease, is to propose that all patients with ASK should be offered radical nephrectomy, en block resection of adjacent organs and chemotherapy, and state that further experience could modify this approach in the future.**

**Remedy:**

We totally agree with your valuable in-deep comments, and we have modified the statement in the conclusion accordingly. Thank you very much. (Please refer to “CONCLUSION,” pp.11)

We are deeply and sincerely honored by the time and effort you spent in reviewing our manuscript. We learned a lot from your much-appreciated remarks and criticism. By incessantly reviewing and revising our manuscript, we were also spurred to study the literature in more depth, which improved not only our insight but also the quality of our paper.